Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín - 2Countdown begins for long-awaited Artemis II moon mission
- 3Well informed: How to Take full advantage of Your Gadgets
- 4As Western heat wave ends, scientists try to make sense of its length and intensity
- 5New trailer for 'Bridgerton' Season 4 teases Benedict's love story: Watch it here
- First Houthi launch toward Israel since war began triggers alerts across the Negev
- Unsold Rams May Be Less expensive Than You Suspect
- Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- Nature's Treats: 10 Organic products That Lift Prosperity
- As world leaders enter climate talks, people in poverty have the most at stake
- How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- \Step by step instructions to Pick the Best Material Organization for Your Home\
